A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Phase 3
1,290
about 4.2 years
40–80
80 sites in AL, AR, AZ +24
What this study is about
Researchers are testing astegolimab, a medication, compared to placebo in people with COPD who are former or current smokers and have had frequent flare-ups. The trial will last for 1533 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Astegolimab
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
monoclonal antibody
Secondary: Absolute change from baseline in health-related quality of life (HRQoL) at Week 52 as assessed through the St. George's Respiratory Questionnaire-COPD (SGRQ-C) total score, Absolute change from baseline in post-bronchodilator forced expiratory volume (FEV1) at Week 52, Absolute change from baseline in the Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS:COPD) total score at Week 52, Proportion of participants with improvement in HRQoL at Week 52
Respiratory